Authentica Global
Markets S&P 500 7,543.64 ▲ 0.81% Nasdaq 26,206.89 ▲ 1.30% Dow Jones 52,487.41 ▲ 0.27% US 10 Yr 4.54 ▼ 0.66% Crude Oil 71.87 ▼ 0.29% Gold 4,131.40 ▼ 0.23% Bitcoin 63,175 ▲ 1.51% FTSE 100 10,472.45 ▼ 0.16% EUR/USD 1.1436 ▲ 0.02% Nikkei 225 67,743.85 ▲ 1.38%
Topic archive

Vera Therapeutics

Reporting, analysis and commentary on Vera Therapeutics from Authentica Global, drawn together from across our coverage.

1 article Latest update: 5 Jul 2026 1 section
Related sections Health
Related topics IgA nephropathy atacicept FDA decision atacicept kidney disease nephrology Berger's disease FDA approval
Tag lead
Close-up of a laboratory scientist preparing a biologic injectable therapy for kidney disease research
Health

IgA Nephropathy Atacicept FDA Decision Looms as Vera Awaits a July 7 Verdict

Vera Therapeutics faces a July 7, 2026 FDA deadline on atacicept, a twice-monthly injection that could become the first dual BAFF and APRIL biologic approved for IgA nephropathy, a leading cause of kidney failure in young adults.

5 Jul 2026 ·8 min read
Keep reading

More paths through this story

This archive gathers Authentica Global coverage of Vera Therapeutics, bringing together the reporting, analysis and commentary connected to the subject.

Related topics

IgA nephropathy atacicept FDA decision atacicept kidney disease nephrology Berger's disease FDA approval Federal Reserve Donald Trump AI infrastructure nonfarm payrolls

Related sections

Health

Latest nearby

Health · 5 Jul 2026 Colorado Enbrel Price Cap Blocked, Pharma Pockets the Win Health · 5 Jul 2026 US Measles Elimination Status 2026 Cracks at 2,170 Cases Health · 5 Jul 2026 Aetna, Cigna Headline ACA Marketplace Insurers Exit 2026 Health · 5 Jul 2026 Dead Skua Marks First H5N1 Bird Flu Australia Detection